Overexpression of S100A9 in human glioma and in-vitro inhibition by aspirin

European Journal of Cancer Prevention

Volumn 22, Issue 6, 2013, Pages 585-595

  Huang, Ning ^a   Chen, Song ^a   Deng, Jinmu ^a   Huang, Qin ^a   Liao, Peng ^a   Wang, Feng ^a   Cheng, Yuan ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

aspirin; cyclooxygenase 2; glioma; S100A9

Indexed keywords

ACETYLSALICYLIC ACID; CALGRANULIN B; MESSENGER RNA; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2;

ADULT; APOPTOSIS; ARTICLE; ASTROCYTE; ASTROCYTOMA; BRAIN TISSUE; CELL VIABILITY; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; GLIOMA; GLIOMA CELL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; ASPIRIN; BLOTTING, WESTERN; BRAIN NEOPLASMS; CALGRANULIN B; CELL PROLIFERATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOMA; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 84885145581     PISSN: 09598278     EISSN: 14735709     Source Type: Journal    
DOI: 10.1097/CEJ.0b013e328364f1c9     Document Type: Article

References (45)

1. Arai K, Yamada T, Nozawa R (2000). Immunohistochemical investigation of migration inhibitory factor-related protein (MRP)-14 expression in hepatocellular carcinoma. Med Oncol 17:183-188.
2. Arai K, Teratani T, Kuruto-Niwa R, Yamada T, Nozawa R (2004). S100A9 expression in invasive ductal carcinoma of the breast: S100A9 expression in adenocarcinoma is closely associated with poor tumour differentiation. Eur J Cancer 40:1179-1187.
3. Arai K, Takano S, Teratani T, Ito Y, Yamada T, Nozawa R (2008). S100A8 and S100A9 overexpression is associated with poor pathological parameters in invasive ductal carcinoma of the breast. Curr Cancer Drug Targets 8: 243-252.
4. Argyriou AA, Kalofonos HP (2009). Molecularly targeted therapies for malignant gliomas. Mol Med 15 (3-4):115-122.
5. Bidwell P, Joh K, Leaver HA, Rizzo MT (2010). Prostaglandin E2 activates cAMP response element-binding protein in glioma cells via a signaling pathway involving PKA-dependent inhibition of ERK. Prostaglandins Other Lipid Mediat 91 (1-2):18-29.
6. Chen S, Cheng Y, Liao P, Deng JM (2012). Construction of S100A9 eukaryotic expression vector and its effect on proliferation of glioma cell line U251. J Third Mil Med Univ 34:1596-1599.
7. Cheng P, Corzo CA, Luetteke N, Yu B, Nagaraj S, Bui MM, et al. (2008). Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer are regulated by S100A9 protein. J Exp Med 205:2235-2249.
8. Cross SS, Hamdy FC, Deloulme JC, Rehman I (2005). Expression of S100 proteins in normal human tissues and common cancers using tissue microarrays: S100A6, S100A9 and S100A11 are all over-expressed in common cancers. Histopathology 46:256-269.
9. Donato R (2001). S100: A multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. Int J Biochem Cell Biol 33:637-668.
10. El-Rifai W, Moskaluk CA, Abdrabbo MK, Harper J, Yoshida C, Riggins GJ, et al. (2002). Gastric cancers overexpress S100A calcium-binding proteins. Cancer Res 62:6823-6826.
11. Elwood PC, Gallagher AM, Duthie GG, Mur LA, Morgan G (2009). Aspirin, salicylates, and cancer. Lancet 373:1301-1309.
12. Gebhardt C, Németh J, Angel P, Hess J (2006). S100A8 and S100A9 in inflammation and cancer. Biochem Pharmacol 72:1622-1631.
13. Ghavami S, Rashedi I, Dattilo BM, Eshraghi M, Chazin WJ, Hashemi M, et al. (2008). S100A8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway. J Leukoc Biol 83: 1484-1492.
14. Guan H, Zhang H, Cai J,Wu J, Yuan J, Li J, et al. (2011). IKBKE is over-expressed in glioma and contributes to resistance of glioma cells to apoptosis via activating NF-kB. J Pathol 223:436-445.
15. Han C, Leng J, Demetris AJ, Wu T (2004). Cyclooxygenase-2 promotes human cholangiocarcinoma growth: Evidence for cyclooxygenase-2-independent mechanism in celecoxib-mediated induction of p21 waf1/cip 1 and p27kip1 and cell cycle arrest. Cancer Res 64:1369-1376.
16. Hembruff SL, Cheng N (2009). Chemokine signaling in cancer: Implications on the tumor micro-environment and therapeutic targeting. Cancer Ther 7 (A):254-267.
17. Hermani A, Hess J, De Servi B, Medunjanin S, Grobholz R, Trojan L, et al. (2005). Calcium-binding proteins S100A8 and S100A9 as novel diagnostic markers in human prostate cancer. Clin Cancer Res 11:5146-5152.
18. Hermani A, De Servi B, Medunjanin S, Tessier PA, Mayer D (2006). S100A8 and S100A9 activate MAP kinase and NF-kappaB signaling pathways and trigger translocation of RAGE in human prostate cancer cells. Exp Cell Res 312:184-197.
19. Hiratsuka S, Watanabe A, Sakurai Y, Akashi-Takamura S, Ishibashi S, Miyake K, et al. (2008). The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat Cell Biol 10:1349-1355.
20. Ichikawa M, Williams R, Wang L, Vogl T, Srikrishna G (2011). S100A8/A9 activate key genes and pathways in colon tumor progression. Mol Cancer Res 9:133-148.
21. Joki T, Heese O, Nikas DC, Bello L, Zhang J, Kraeft SK, et al. (2000). Expression of cyclooxygenase-2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398. Cancer Res 60:4926-4931.
22. Källberg E, Vogl T, Liberg D, Olsson A, Björk P, Wikstrom P, et al. (2012). S100A9 interaction with TLR4 promotes tumor growth. PLoS One 7: E34207.
23. Kawai H, Minamiya Y, Takahashi N (2011). Prognostic impact of S100A9 overexpression in non-small cell lung cancer. Tumor Biol 32:641-646.
24. Kim HJ, Kang HJ, Lee H, Lee ST, Yu MH, Kim H, et al. (2009). Identification of S100A8 and S100A9 as serological markers for colorectal cancer. J Proteome Res 8:1368-1379.
25. Kim SR, Bae MK, Kim JY, Wee HJ, Yoo MA, Bae SK (2009). Aspirin induces apoptosis through the blockade of IL-6-STAT3 signaling pathway in human glioblastoma A172 cells. Biochem Biophys Res Commun 387:342-347.
26. Kim WJ, Kim SK, Jeong P, Yun SJ, Cho IC, Kim IY, et al. (2011). A four-gene signature predicts disease progression in muscle invasive bladder cancer. Mol Med 17 (5-6):478-485.
27. Li MX, Xiao ZQ, Liu YF, Chen YH, Li C, Zhang PF, et al. (2009). Quantitative proteomic analysis of differential proteins in the stroma of nasopharyngeal carcinoma and normal nasopharyngeal epithelial tissue. J Cell Biochem 106:570-579.
28. Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, et al. (2001). Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 276:18563-18569.
29. Minami S, Sato Y, Matsumoto T, Kageyama T, Kawashima Y, Yoshio K, et al. (2010). Proteomic study of sera from patients with bladder cancer: Usefulness of S100A8 and S100A9 proteins. Cancer Genomics Proteomics 7:181-189.
30. Mischke D, Korge BP, Marenholz I, Volz A, Ziegler A (1996). Genes encoding structural proteins of epidermal cornification and S100 calcium-binding proteins form a gene complex(''epidermal differentiation complex'') on human chromosome 1q21. J Invest Dermatol 106:989-992.
31. Moon A, Yong HY, Song JI, Cukovic D, Salagrama S, Kaplan D, et al. (2008). Global gene expression profiling unveils S100A8/A9 as candidate markers in H-ras-mediated human breast epithelial cell invasion. Mol Cancer Res 6:1544-1553.
32. Myung J, Cho BK, Kim YS, Park SH (2010). Snail and Cox-2 expressions are associated with WHO tumor grade and survival rate of patients with gliomas. Neuropathology 30:224-231.
33. Nemeth J, Stein I, Haag D, Riehl A, Longerich T, Horwitz E, et al. (2009). S100A8 and S100A9 are novel nuclear factor kappa B target genes during malignant progression of murine and human liver carcinogenesis. Hepatology 50:1251-1262.
34. O'Dwyer D, Ralton LD, O'Shea A, Murray GI (2011). The proteomics of colorectal cancer: Identification of a protein signature associated with prognosis. PLoS One 6:e27718.
35. Payner T, Leaver HA, Knapp B, Whittle IR, Trifan OC, Miller S, et al. (2006). Microsomal prostaglandin E synthase-1 regulates human glioma cell growth via prostaglandin E(2)-dependent activation of type II protein kinase A. Mol Cancer Ther 5:1817-1826.
36. Rice PL,Washington M, Schleman S, Beard KS, Driggers LJ, Ahnen DJ (2003). Sulindac sulfide inhibits epidermal growth factor-induced phosphorylation of extracellular-regulated kinase 1/2 and Bad in human colon cancer cells. Cancer Res 63:616-620.
37. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW (2011). Effect of daily aspirin on long-term risk of death due to cancer: Analysis of individual patient data from randomised trials. Lancet 377:31-41.
38. Sareddy GR, Geeviman K, Ramulu C, Babu PP (2012). The nonsteroidal anti-inflammatory drug celecoxib suppresses the growth and induces apoptosis of human glioblastoma cells via the NF-kB pathway. J Neurooncol 106:99-109.
39. Shono T, Tofilon PJ, Bruner JM, Owolabi O, Lang FF (2001). Cyclooxygenase-2 expression in human gliomas: Prognostic significance and molecular correlations. Cancer Res 61:4375-4381.
40. Swiatek-Machado K, Kaminska B (2013). STAT signaling in glioma cells. Adv Exp Med Biol 986:189-208.
41. Turovskaya O, Foell D, Sinha P, Vogl T, Newlin R, Nayak J, et al. (2008). RAGE, carboxylated glycans and S100A8/A9 play essential roles in colitisassociated carcinogenesis. Carcinogenesis 29:2035-2043.
42. Wagner EF, Nebreda AR (2009). Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9:537-549.
43. Wakimoto N, Wolf I, Yin D, O'Kelly J, Akagi T, Abramovitz L, et al. (2008). Nonsteroidal anti-inflammatory drugs suppress glioma via 15-hydroxyprostaglandin dehydrogenase. Cancer Res 68:6978-6986.
44. Wen PY, Kesari S (2008). Malignant gliomas in adults. N Engl J Med 359: 492-507.
45. Yoshimoto K, Bando Y, Kudo E, Shimada M, Sano T (2010). High expression of toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer. Br J Cancer 102:908-1015.